Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Study on animal model may impact treatment of stroke

The results of two studies published in the current issue of Cell Transplantation (19:9) using animal models of cerebral ischemia and ischemic stroke in rats may significantly impact the treatment of stroke in humans.

2 Dec 2010

Bone marrow stromal stem cells may aid in stroke recovery: Research

A research study from the Farber Institute for Neurosciences and the Department of Neuroscience at Thomas Jefferson University determines bone marrow stromal stem cells may aid in stroke recovery. The results can be found in Cell Transplantation, The Regenerative Medicine Journal, issue 19(9).

2 Dec 2010

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline Therapeutics, Inc. today announced that two abstracts featuring SL-401 clinical efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and pre-clinical activity in chronic myeloid leukemia (CML) have been selected for presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH) to be held in Orlando, FL from December 4-7, 2010.

2 Dec 2010

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VPRIV (velaglucerase alfa), an enzyme replacement therapy (ERT) for long-term use in pediatric and adult type 1 Gaucher disease.

1 Dec 2010

ASH to host annual meeting for blood disorders at Orange Convention Center

The American Society of Hematology (ASH) will host its 52nd annual meeting at the Orange County Convention Center in Orlando, FL, December 4-7. More than 20,000 attendees are expected for this event, which will highlight emerging research trends in the diagnosis, treatment, and understanding of blood disorders.

1 Dec 2010

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

Study finds abdominal fat as a risk factor for osteoporosis, bone loss in women

For years, it was believed that obese women were at lower risk for developing osteoporosis, and that excess body fat actually protected against bone loss. However, a study presented today at the annual meeting of the Radiological Society of North America (RSNA) found that having too much internal abdominal fat may, in fact, have a damaging effect on bone health.

30 Nov 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Stem cell treatment may help treat low back pain

Lower back pain affects many people and may be caused by degeneration of the discs between the vertebrae. Treatment for the condition using stem cells may be an alternative to today's surgical procedures. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

28 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Elbit Imaging closes transaction with Enter

Elbit Imaging Ltd. announced today that, further to its announcement dated September 13, 2010, it has successfully closed the transaction with Enter Holdings 1 Ltd. and Enter's controlling shareholders.

25 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010

Embryonic stem cell research has not made good on taxpayer investment

In 2004 Robert Klein, chairman of the California Institute of Regenerative Medicine (CIRM), helped pass Proposition 71, establishing the CIRM with a state taxpayer-funded $3 billion budget for ten years. The measure was passed with promises of affordable cures for virtually all diseases, cures specifically from embryonic stem cells and cloning, as well as tremendous financial payback for the citizens of California. The Los Angeles Times recently noted that Klein plans to seek up to $3 billion more from state taxpayers for his stem cell fiefdom.

25 Nov 2010

Cord Blood America shares web site post on Thanksgiving Day

On this day before Thanksgiving, a day when our entire nation gives thanks for its blessing, Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, would like to share with its investors a post from its web site by Dr. Geoffrey O'Neill, CBAI Vice President, Operations.

24 Nov 2010

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

A hormone made by the body may be a potential therapeutic tool for the treatment of two anemic blood disorders beta-thalassemia and hemochromatosis. The new research was led by scientists at Weill Cornell Medical College and published in the Journal of Clinical Investigation and the journal Blood.

24 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

National Marrow Donor Program adopts IBM's WebSphere Lombardi Business Process Management software

IBM announced today that the National Marrow Donor Program® (NMDP) has adopted IBM's WebSphere Lombardi Business Process Management (BPM) software to help automate its donor and patient management process. Both processes are critical to facilitate the matching of donors to patients needing cellular transplants.

20 Nov 2010

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that the Company will present new data at the American Society of Nephrology meeting being held in Denver, Colorado, on its late-stage investigational drug Soluble Ferric Pyrophosphate, which is being studied for the treatment of iron-deficiency anemia in ESRD patients.

20 Nov 2010

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010